<--- Back to Details
First PageDocument Content
Pharmaceuticals policy / Pharmacology / Pharmaceutics / Therapeutics / Prescription Drug User Fee Act / Center for Drug Evaluation and Research / Drug Master File / Generic drug / Abbreviated New Drug Application / Food and Drug Administration / Pharmaceutical industry / Pharmaceutical sciences
Pharmaceuticals policy
Pharmacology
Pharmaceutics
Therapeutics
Prescription Drug User Fee Act
Center for Drug Evaluation and Research
Drug Master File
Generic drug
Abbreviated New Drug Application
Food and Drug Administration
Pharmaceutical industry
Pharmaceutical sciences

GDUFA Public Mtg Min[removed]

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 45,77 KB

Share Document on Facebook

Similar Documents

CENTER FOR DRUG EVALUATION AND RESEARCH DRUG SAFETY PRIORITIES 2017

DocID: 1ueGS - View Document

CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208573Orig1s000 SUMMARY REVIEW

DocID: 1t19G - View Document

CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022526Orig1s000 SUMMARY REVIEW

DocID: 1sZi5 - View Document

MEMORANDUM DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH

DocID: 1sPXO - View Document

Abstract # 2639 Enhanced (Q)SAR Models for Prediction Rodent Carcinogenicity Naomi L. Kruhlak1, Dongyu Guo1, Kevin P. Cross2, Lidiya Stavitskaya1 FDA Center for Drug Evaluation and Research (CDER), 10903 New Hampshire A

DocID: 1swgc - View Document